These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24007292)

  • 21. Interaction of human CYP17 (P-450(17alpha), 17alpha-hydroxylase-17,20-lyase) with cytochrome b5: importance of the orientation of the hydrophobic domain of cytochrome b5.
    Lee-Robichaud P; Kaderbhai MA; Kaderbhai N; Wright JN; Akhtar M
    Biochem J; 1997 Feb; 321 ( Pt 3)(Pt 3):857-63. PubMed ID: 9032476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
    Njar VC; Brodie AM
    Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of RNA interference inhibiting rat ovarian androgen biosynthesis by depressing 17alpha-hydroxylase/17, 20-lyase activity in vivo.
    Li Y; Liang XY; Wei LN; Xiong YL; Yang X; Shi HG; Yang ZH
    Reprod Biol Endocrinol; 2009 Jul; 7():73. PubMed ID: 19615041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen synthesis in a songbird: a study of cyp17 (17alpha-hydroxylase/C17,20-lyase) activity in the zebra finch.
    Schlinger BA; Lane NI; Grisham W; Thompson L
    Gen Comp Endocrinol; 1999 Jan; 113(1):46-58. PubMed ID: 9882543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450 17alpha hydroxylase/17,20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells.
    Liu Y; Yao ZX; Papadopoulos V
    Mol Endocrinol; 2005 Jul; 19(7):1918-31. PubMed ID: 15761033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17.
    Gupta MK; Guryev OL; Auchus RJ
    Arch Biochem Biophys; 2003 Oct; 418(2):151-60. PubMed ID: 14522586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tight binding of cytochrome b
    Kim D; Kim V; McCarty KD; Guengerich FP
    J Biol Chem; 2021; 296():100571. PubMed ID: 33753170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations.
    Auchus RJ; Miller WL
    Mol Endocrinol; 1999 Jul; 13(7):1169-82. PubMed ID: 10406467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17,20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling.
    Patocs A; Liko I; Varga I; Gergics P; Boros A; Futo L; Kun I; Bertalan R; Toth S; Pazmany T; Toth M; Szücs N; Horanyi J; Glaz E; Racz K
    J Steroid Biochem Mol Biol; 2005 Nov; 97(3):257-65. PubMed ID: 16176874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5.
    Geller DH; Auchus RJ; Miller WL
    Mol Endocrinol; 1999 Jan; 13(1):167-75. PubMed ID: 9892022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
    Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
    Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
    J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP17 inhibitors for prostate cancer treatment--an update.
    Moreira VM; Salvador JA; Vasaitis TS; Njar VC
    Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
    Salvador JA; Pinto RM; Silvestre SM
    J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
    Tigli H; Yazici H; Dalay N
    Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of intermolecular interactions of microsomal cytochrome P450s CYP17 and CYP21 involved in steroid hormone biosynthesis.
    Sushko TA; Gilep AA; Usanov SA
    Biochemistry (Mosc); 2012 Jun; 77(6):585-92. PubMed ID: 22817457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
    Owen CP
    Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.